Home / Science / AI Designs Drugs, Human Trials Begin Soon
AI Designs Drugs, Human Trials Begin Soon
24 Apr
Summary
- Isomorphic Labs, a Google DeepMind spinoff, starts human trials for AI-designed drugs.
- AlphaFold 3, an advanced AI, predicts complex molecular interactions for drug discovery.
- The company aims to 'solve all disease' with its potent, low-dose drug designs.
Isomorphic Labs, a spinoff from Google DeepMind, is preparing to initiate human trials for drugs designed by its advanced AI technology. The company leverages DeepMind's AlphaFold platform, which revolutionized protein structure prediction and is now advancing drug discovery. AlphaFold 3, released in 2024, models not only proteins but also DNA, RNA, and their interactions, crucial for identifying how small molecules bind to targets.
With a mission to 'solve all disease,' Isomorphic Labs has developed IsoDDE, a proprietary engine that reportedly doubles AlphaFold 3's accuracy. The startup has formed partnerships with major pharmaceutical companies and is advancing its own pipeline in oncology and immunology. Their AI-designed molecules are engineered for high potency, enabling lower dosages and potentially reducing side effects.
